Ossianix Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Debt

  • Latest Deal Amount
  • $400K

  • Investors
  • 3

Ossianix General Information

Description

Operator of a protein engineering company intended to develop biological therapeutics. The company offers products using single-domain antibodies from sharks and specializes in treating nervous system disorders, inflammation, and metabolic and muscular diseases, it has also developed a highly efficient blood-brain barrier antibody transporter with proven concepts in non-human primates transporting various therapeutics including peptides, antibodies, large enzymes, enabling healthcare providers to cure patients and improve their lives

Contact Information

Website
www.ossianix.co.uk
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road, Hertfordshire
  • Stevenage SG1 2FX
  • England, United Kingdom
+44 01438 000000
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road, Hertfordshire
  • Stevenage SG1 2FX
  • England, United Kingdom
+44 01438 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ossianix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Debt - General 17-May-2022 $400K 00.000 Completed Generating Revenue
3. Early Stage VC 24-Oct-2014 00000 00000 Completed Generating Revenue
2. Seed Round 23-May-2013 $565K $565K Completed Startup
1. Grant 25-Jul-2011 Completed Startup
To view Ossianix’s complete valuation and funding history, request access »

Ossianix Patents

  • 46

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 25

    Granted

  • 21

    Pending

  • 000

    Expiring in next 12 mo

Ossianix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3227486-A1 Deimmunized vnar domains and scaffolds Pending 17-Aug-2021
AU-2022329980-A1 Deimmunized vnar domains and scaffolds Pending 17-Aug-2021 00000000000
EP-4388001-A1 Deimmunized vnar domains and scaffolds Pending 17-Aug-2021 00000000000
US-11345742-B1 Shark vnars for treating covid-19 Active 07-Jun-2021 000000000 0
EP-4244249-A1 High affinity human and monkey specific tfr-1 vnars Pending 11-Nov-2020 C07K16/2881
To view Ossianix’s complete patent history, request access »

Ossianix Executive Team (4)

Name Title Board Seat
Frank Walsh Ph.D Co-Founder, Chief Executive Officer & Board Member
Steve Moore Ph.D Chief Operating Officer & Site Director & Operations Manager
J Lynn Rutkowski Ph.D Co-Founder, Chief Scientific Officer & Board Member
Corey Goodman Ph.D Co-Founder
To view Ossianix’s complete executive team members history, request access »

Ossianix Board Members (6)

Name Representing Role Since
Barbara Schilberg JD BioAdvance Board Observer 000 0000
Frank Walsh Ph.D Ossianix Co-Founder, Chief Executive Officer & Board Member 000 0000
J Lynn Rutkowski Ph.D Ossianix Co-Founder, Chief Scientific Officer & Board Member 000 0000
Michael Owen Ph.D Self Chairman 000 0000
You’re viewing 4 of 6 board members. Get the full list »

Ossianix Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ossianix Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioAdvance Venture Capital Minority 000 0000 000000 0
H. Lundbeck Corporation Minority 000 0000 000000 0
The ALS Association Corporation 000 0000 000000 0
To view Ossianix’s complete investors history, request access »

Ready to get started?

Request a free trial

Ossianix FAQs

  • When was Ossianix founded?

    Ossianix was founded in 2010.

  • Who is the founder of Ossianix?

    Frank Walsh Ph.D, J Lynn Rutkowski Ph.D, and Corey Goodman Ph.D are the founders of Ossianix.

  • Who is the CEO of Ossianix?

    Frank Walsh Ph.D is the CEO of Ossianix.

  • Where is Ossianix headquartered?

    Ossianix is headquartered in Stevenage, United Kingdom.

  • What is the size of Ossianix?

    Ossianix has 9 total employees.

  • What industry is Ossianix in?

    Ossianix’s primary industry is Drug Discovery.

  • Is Ossianix a private or public company?

    Ossianix is a Private company.

  • What is Ossianix’s current revenue?

    The current revenue for Ossianix is 00000.

  • How much funding has Ossianix raised over time?

    Ossianix has raised $1.17M.

  • Who are Ossianix’s investors?

    BioAdvance, H. Lundbeck, and The ALS Association have invested in Ossianix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »